Related Experiment Video
Updated: Feb 7, 2026

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
Published on: June 28, 2018
PCV13 vaccination impact: A multicenter study of pneumonia in 10 pediatric hospitals in Argentina
Angela Gentile1, Julia Bakir1, Verónica Firpo2
1Epidemiology, Ricardo Gutiérrez Children's Hospital, Buenos Aires, Argentina.
Insights
The introduction of Pneumococcal Conjugate Vaccine 13 (PCV13) in Argentina significantly reduced hospitalizations for Consolidated Pneumonia (CP) and Pneumococcal Pneumonia (PP) in children under five. The vaccine also decreased PP rates in older children and reduced the prevalence of PCV13 serotypes.
Area of Science:
- * Public Health and Epidemiology
- * Vaccinology and Infectious Diseases
- * Pediatric Medicine
Background:
- * Argentina implemented the 13-valent pneumococcal conjugate vaccine (PCV13) in its National Immunization Program in 2012, using a 2+1 schedule for children under two years old.
- * Initial vaccine coverage rates for the first and third doses were 69% and 41.0% in 2012, increasing to 98% and 86% by 2013, and 99% and 89% by 2014.
Purpose of the Study:
- * To assess the impact of PCV13 introduction on the burden of Consolidated Pneumonia (CP) and Pneumococcal Pneumonia (PP) in hospitalized children.
- * To describe the epidemiological and clinical characteristics of Pneumococcal Pneumonia (PP) cases during the three years following PCV13 implementation.
Main Methods:
- * A hospital-based study was conducted across 10 pediatric surveillance units in Argentina.
- * Discharge rates for CP and PP per 10,000 hospital discharges were compared between the pre-vaccination period (2007-2011), the intervention year (2012), and the post-vaccination period (2013-2014).
Main Results:
- * Significant reductions in CP and PP discharge rates were observed in children under 5 years old post-PCV13 introduction.
- * Specifically, CP discharge rates decreased by 10.2% in 2012 and 24.8% in the post-vaccination period; PP rates dropped by 59.5% in 2012 and 68.8% post-vaccination.
- * A notable decrease in PCV13 serotypes was observed, from 83.0% in 2012 to 64.2% in the post-vaccination period (p = 0.039).
Conclusions:
- * The introduction of PCV13 led to a significant decrease in hospital discharge rates for both CP and PP among children under five.
- * The study also observed a significant reduction in PP discharge rates among children aged five years and older.
- * The findings support the effectiveness of PCV13 in reducing the burden of pneumococcal disease in a national immunization program setting.
Introduction:
In 2012, PCV13 was introduced into the National Immunization Program in Argentina, 2+1 schedule for children <2 years. Coverage rates for 1st and 3rd doses were 69% and 41.0% in 2012, 98% and 86% in 2013; 99% and 89% in 2014, respectively. The aims of this study were to evaluate impact of PCV13 on Consolidated Pneumonia (CP) and Pneumococcal Pneumonia (PP) burden, and to describe epidemiological-clinical pattern of PP during the three-year period following vaccine introduction.
Methods:
Hospital-based study at 10 pediatric surveillance units in Argentina. CP and PP discharge rates per 10,000 hospital discharges were compared between the pre-vaccination period 2007-2011 (preVp), the year of intervention (2012) and the post-vaccination period 2013-2014 (postVp).
Results:
Significant reduction in CP and PP discharge rates was observed in patients <5 years [% reduction (95%CI)]: 10.2% (6.3; 14.0) in 2012 and 24.8% (21.3; 28.2) in postVp for CP discharge rate; 59.5% (48.0; 68.5) in 2012 and 68.8% (58.3; 76.6) in postVp for PP discharge rate. Significant changes were also observed in children ≥5 years, mainly in PP discharge rate. A total of 297 PP cases were studied; 59.3% male; 31.3% <2 years; 42.9% had received PCV13 in 2012 and 84.5% in posVp. Case fatality rate was 3.4%. PCV13 serotypes decreased from 83.0% (39/47) in 2012 to 64.2% (52/81) in postVp, p = 0.039.
Conclusions:
After PCV13 introduction, significant reduction in CP and PP discharge rates was observed in hospitalized children <5 years. In patients ≥5 years, PP discharge rate also decreased significantly.
More Related Videos
14:45Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
Published on: September 16, 2012
09:37Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique
Published on: September 23, 2022
Related Concept Videos
Hospitals-II
Nurses that work in...
Vaccinations
Hospitals-I
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology
Impact of Groups on Groups